A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin
- 1 October 1985
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 38 (4), 394-401
- https://doi.org/10.1038/clpt.1985.193
Abstract
Debrisoquin hydroxylation capacity determined as the ratio of debrisoquin to 4-OH-debrisoquin (DMR) in urine after a single oral dose (10 mg) was studied in 52 nuclear families comprising 226 subjects. The relative importance of genetic and environment factors for DMR was studied by path analysis. There was a significant negative correlation between DMR and coffee intake but no significant correlations between DMR and sex, age, alcohol intake, or smoking habits. Path analysis showed that genetic heritability was 0.79 while cultural heritability was only 0.06. Complex segregation analysis gave evidence for a major locus with incomplete dominance (d = 0.28) between a recessive and an additive gene. The frequency of the major gene was 0.31, allowing an estimate of the frequency of slow hydroxylators in the Swedish population of 9.4%. There was also evidence for a multifactorial component accounting for 14% of the total variation. It was not possible to distinguish between the different genotypes within the rapid hydroxylator phenotype. Our data agree with previous studies in British and German populations showing that two alleles at a major autosomal locus can explain most of the observed variation in DMR. The frequency of slow hydroxylators in Sweden is very similar to that reported in other European studies. The debrisoquin metabolic phenotype seems to be extensively controlled by a monogenic system and not significantly influenced by environmental factors or age.This publication has 17 references indexed in Scilit:
- Genetically determined oxidation capacity and the disposition of debrisoquine.British Journal of Clinical Pharmacology, 1983
- Comparative pharmacogenetics of sparteine and debrisoquineClinical Pharmacology & Therapeutics, 1983
- E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylationClinical Pharmacology & Therapeutics, 1981
- Path analysis under generalized assortative matingGenetics Research, 1979
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- A Population and Familial Study of the Defective Alicyclic Hydroxylation of Debrisoquine among EgyptiansXenobiotica, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Skewness in Commingled DistributionsBiometrics, 1976
- RESOLUTION OF CULTURAL AND BIOLOGICAL INHERITANCE BY PATH-ANALYSIS1976
- Insufficient parahydroxylation as a cause of diphenylhydantoin toxicityNeurology, 1964